ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
March 19, 2020
Mr. Squarer, a global biopharmaceutical leader, brings extensive oncology commercialization expertise as Company prepares to submit BLA in Q3 2020
Read the full press release
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
February 20, 2019
Combination trial to evaluate safety and anti-tumor activity of agents that target B-cell cancers
Read the full press release
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
February 13, 2019
Combination of antibody drug conjugate and checkpoint inhibitor being evaluated for treatment of relapsed or refractory diffuse large B-cell, mantle cell and follicular lymphomas
Read the full press release
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
January 16, 2019
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors
Read the full press release
ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors
January 04, 2019
Potential for new immune-oncology therapy using an antibody drug conjugate that targets regulatory T cells
Read the full press release
ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
December 05, 2018
ADCT-402 and ADCT-301 Data presented at 60th American Society of Hematology (ASH) Annual Meeting
Read the full press release
ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
November 27, 2018
Trial of CD22-targeting antibody drug conjugate being led by The University of Texas MD Anderson Cancer Center
Read the full press release
ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting
November 14, 2018
New clinical data highlight potential of novel pyrrolobenzodiazepine-based antibody drug conjugates for the treatment of relapsed or refractory lymphomas
Read the full press release
Sun Pharma Announces U.S. FDA Approval of CEQUA™ to Treat Dry Eye Disease
August 16, 2018
CEQUA (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only dry eye treatment to combine cyclosporine A with nanomicellar technology
Read the full press release
Sun Pharma Announces US FDA Acceptance of NDA for OTX-101
December 27, 2017
OTX-101 is being evaluated for treatment of dry eye disease. Phase 3 Confirmatory Study Data Demonstrated Potential of OTX-101 to Offer Patients Improved Tear Production Coupled With Faster Onset of Action. Sun Pharma is developing OTX-101 for global markets
Read the full press release
Auven Therapeutics Announces Closing of Sale of Ocular Technologies Sarl, Holding Entity for Seciera™ for Treatment of Dry Eye Disease
January 6, 2017
Achievement of primary endpoint of increased tear production and key secondary endpoints in confirmatory Phase 3 clinical trial highlights Seciera’s&trade competitive value proposition, validates Auven’s investment model
Read the full press release
Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye
January 4, 2017
SecieraT™ Meets Primary and Key Secondary Endpoints in Pivotal Trial
Shows efficacy at 12 weeks of treatment. Sun Pharma is developing Seciera™ for global markets
Read the full press release
Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma
October 26, 2016
- Ocular Technologies’ key development program asset, Seciera™ for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial.
- Auven to receive $40 million upfront payment, substantial contingent development and commercial milestone payments, and royalties.
Read the full press release
Sun's press release
Auven Therapeutics Announces Completion of Enrollment in Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease
August 22, 2016
-Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end.
-Seciera poised for significant commercial opportunity as a highly competitive entrant in dry eye disease market.
Read the full press release
Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease
March 03, 2016
-Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing.
-Commercial assessment confirms Seciera has the potential for $1 billion in sales worldwide
Read the full press release
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis
January 21, 2016
Auven Therapeutics, a global private equity company focused on accelerated development of breakthrough therapeutic drugs, and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis.
Read the full press release